Pharmacogenetic Clinical Randomised Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI With High-Dose Irinotecan (HD-FOLFIRI) in Metastatic Colorectal Cancer Patients According to Their UGT1A 1 Genotype

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0348-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

A Randomised, Double-Blind, Placebo-Controlled Multi-Centre Phase III Trial of XELIRI/FOLFIRI Plus Simvastatin for Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2015English

A Phase I Study of Intravenous Aflibercept With FOLFIRI in Japanese Patients With Previously Treated Metastatic Colorectal Cancer

Investigational New Drugs
OncologyPharmacology
2012English

FOLFIRI® and Bevacizumab in First-Line Treatment for Colorectal Cancer Patients: Safety, Efficacy and Genetic Polymorphisms

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2014English

An Open, Multi-Centre, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Paclitaxel, UFT, and Leucovorin in Patients With Advanced Gastric Cancer

British Journal of Cancer
Cancer ResearchOncology
2006English

P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Erratum To: UDP-glucuronosyltransferase 1A1*6 and *28 Polymorphisms as Indicators of Initial Dose Level of Irinotecan to Reduce Risk of Neutropenia in Patients Receiving FOLFIRI for Colorectal Cancer

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2016English

Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) With Erlotinib (OSI-774): Early Termination Due to Increased Toxicities

Clinical Cancer Research
Cancer ResearchOncology
2004English

Bifractionated CPT-11 With LV5FU2 Infusion (FOLFIRI-3) in Combination With Bevacizumab: Clinical Outcomes in First-Line Metastatic Colorectal Cancers According to Plasma Angiopoietin-2 Levels

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy